{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:55:00Z","timestamp":1792446900163,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.pnpbp.2017.04.026","type":"journal-article","created":{"date-parts":[[2017,4,23]],"date-time":"2017-04-23T10:30:58Z","timestamp":1492943458000},"page":"217-226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":222,"special_numbering":"PC","title":["Effect of antidepressant treatment on peripheral inflammation markers \u2013 A meta-analysis"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8353-7820","authenticated-orcid":false,"given":"Magdalena","family":"Wi\u0119d\u0142ocha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Marcinowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Krupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlena","family":"Janoska-Ja\u017adzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Janus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika","family":"D\u0119bowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mosio\u0142ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Napoleon","family":"Waszkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Szulc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2\u20133","key":"10.1016\/j.pnpbp.2017.04.026_bb0005","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jad.2012.03.033","article-title":"Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study","volume":"141","author":"Abbasi","year":"2012","journal-title":"J. Affect. Disord."},{"issue":"7","key":"10.1016\/j.pnpbp.2017.04.026_bb0010","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hup.717","article-title":"IL6 levels decrease with SSRI treatment in patients with major depression","volume":"20","author":"Basterzi","year":"2005","journal-title":"Hum Psychopharmacol."},{"issue":"9","key":"10.1016\/j.pnpbp.2017.04.026_bb0015","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00213-015-4044-5","article-title":"Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?","volume":"233","author":"Baumeister","year":"2016","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.pnpbp.2017.04.026_bb0020","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/PSY.0b013e3181f883ce","article-title":"Selective serotonin reuptake inhibitor suppression of HIV infectivity and replication","volume":"72","author":"Benton","year":"2010","journal-title":"Psychosom. Med."},{"issue":"7","key":"10.1016\/j.pnpbp.2017.04.026_bb0025","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00213-013-3322-3","article-title":"Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial","volume":"231","author":"Brunoni","year":"2014","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2017.04.026_bb0030","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbi.2011.07.239","article-title":"Treatment response and cognitive impairment in major depression: association with C-reactive protein","volume":"26","author":"Chang","year":"2012","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.pnpbp.2017.04.026_bb0035","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1155\/2010\/573594","article-title":"Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males","volume":"2010","author":"Chen","year":"2010","journal-title":"Mediat. Inflamm."},{"issue":"1","key":"10.1016\/j.pnpbp.2017.04.026_bb0040","first-page":"25","article-title":"Connection between inflammatory markers, antidepressants and depression","volume":"51","author":"Crnkovi\u0107","year":"2012","journal-title":"Acta Clin. Croat."},{"issue":"1","key":"10.1016\/j.pnpbp.2017.04.026_bb0045","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/acps.12576","article-title":"Recovery from major depressive disorder episode after non-pharmacological treatment is associated with normalized cytokine levels","volume":"134","author":"Dahl","year":"2016","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2017.04.026_bb0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jpsychires.2016.01.008","article-title":"Pro-inflammatory cytokines and psychotherapy in depression: Results from a randomized clinical trial","volume":"75","author":"Del Grande da Silva","year":"2016","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2017.04.026_bb0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"issue":"67","key":"10.1016\/j.pnpbp.2017.04.026_bb0060","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","article-title":"A meta-analysis of cytokines in major depression","volume":"2010","author":"Dowlati","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2017.04.026_bb0065","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1017\/S1092852900013754","article-title":"The subgenual anterior cingulate cortex in mood disorders","volume":"13","author":"Drevets","year":"2008","journal-title":"CNS Spectr."},{"issue":"1-2","key":"10.1016\/j.pnpbp.2017.04.026_bb0070","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.neuint.2007.06.037","article-title":"Neurohormonal-cytokine interactions: implications for inflammation, common human diseases and well-being","volume":"52","author":"Elenkov","year":"2008","journal-title":"Neurochem. Int."},{"issue":"2","key":"10.1016\/j.pnpbp.2017.04.026_bb0075","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.pnpbp.2007.09.015","article-title":"Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder","volume":"32","author":"Eller","year":"2008","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.04.026_bb0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/NDT.S16382","article-title":"Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg\/day: a preliminary observation","volume":"7","author":"Fornaro","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"10.1016\/j.pnpbp.2017.04.026_bb0090","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jad.2012.08.007","article-title":"Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds","volume":"145","author":"Fornaro","year":"2013","journal-title":"J. Affect. Disord."},{"issue":"4","key":"10.1016\/j.pnpbp.2017.04.026_bb0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/BF02900219","article-title":"1997. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission","volume":"247","author":"Frommberger","year":"1997","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2017.04.026_bb0100","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/sj.mp.4001032","article-title":"Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH\/NE states","volume":"7","author":"Gold","year":"2002","journal-title":"Mol. Psychiatry"},{"issue":"3\u20134","key":"10.1016\/j.pnpbp.2017.04.026_bb0105","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000444220","article-title":"Effect of mirtazapine treatment on serum levels of brain-derived neurotrophic factor and tumor necrosis factor-\u03b1 in patients of major depressive disorder with severe depression","volume":"97","author":"Gupta","year":"2016","journal-title":"Pharmacology"},{"key":"10.1016\/j.pnpbp.2017.04.026_bb0110","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jpsychires.2015.04.026","article-title":"Does escitalopram reduce neurotoxicity in major depression?","volume":"66-67","author":"Halaris","year":"2015","journal-title":"J. Psychiatr. Res."},{"issue":"12","key":"10.1016\/j.pnpbp.2017.04.026_bb0115","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1038\/npp.2011.132","article-title":"The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis","volume":"36","author":"Hannestad","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pnpbp.2017.04.026_bb0120","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.3390\/ijms16047796","article-title":"Inflammatory biomarkers as differential predictors of antidepressant response","volume":"16","author":"Hashimoto","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.pnpbp.2017.04.026_bb0125","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.euroneuro.2008.08.001","volume":"18","author":"Hern\u00e1ndez","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.04.026_bb0130","doi-asserted-by":"crossref","first-page":"267871","DOI":"10.1155\/2013\/267871","article-title":"Effect of selective serotonin reuptake inhibitors and immunomodulator on cytokines levels: an alternative therapy for patients with major depressive disorder","volume":"2013","author":"Hernandez","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.pnpbp.2017.04.026_bb0135","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.pnpbp.2017.04.026_bb0140","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1017\/S0033291712000128","article-title":"Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis","volume":"42","author":"Hiles","year":"2012","journal-title":"Psychol. Med."},{"issue":"1","key":"10.1016\/j.pnpbp.2017.04.026_bb0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0893-133X(00)00089-0","article-title":"Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine","volume":"23","author":"Hinze-Selch","year":"2000","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2017.04.026_bb0150","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.psychres.2009.04.013","article-title":"Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder","volume":"178","author":"Jazayeri","year":"2010","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.pnpbp.2017.04.026_bb0155","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00702-011-0668-8","article-title":"New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid\/3-hydroxykynurenine ratio","volume":"119","author":"Kocki","year":"2012","journal-title":"J. Neural. Transm. (Vienna)"},{"issue":"12","key":"10.1016\/j.pnpbp.2017.04.026_bb0160","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/jamapsychiatry.2014.1611","article-title":"Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials","volume":"71","author":"K\u00f6hler","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2017.04.026_bb0165","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1055\/s-2002-36390","article-title":"Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine","volume":"35","author":"Kraus","year":"2002","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2017.04.026_bb0170","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0893-133X(99)00134-7","article-title":"Cytokine production and treatment response in major depressive disorder","volume":"22","author":"Lanquillon","year":"2000","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2017.04.026_bb0175","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.psyneuen.2012.05.005","article-title":"Venlafaxine inhibits the upregulation of plasma tumor necrosis factor-alpha (TNF-\u03b1) in the Chinese patients with major depressive disorder: a prospective longitudinal study","volume":"38","author":"Li","year":"2013","journal-title":"Psychoneuroendocrinology"},{"issue":"4","key":"10.1016\/j.pnpbp.2017.04.026_bb0180","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1440-1681.2008.05077.x","article-title":"Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling","volume":"36","author":"Mackay","year":"2009","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"4","key":"10.1016\/j.pnpbp.2017.04.026_bb0185","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0165-0327(95)00028-L","article-title":"Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression","volume":"34","author":"Maes","year":"1995","journal-title":"J. Affect. Disord."},{"issue":"11","key":"10.1016\/j.pnpbp.2017.04.026_bb0190","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1006\/cyto.1997.0238","article-title":"Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression","volume":"9","author":"Maes","year":"1997","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.pnpbp.2017.04.026_bb0195","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/hup.2525","article-title":"Evaluation of interleukin-6 and serotonin as biomarkers to predict response to fluoxetine","volume":"31","author":"Manoharan","year":"2016","journal-title":"Hum Psychopharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2017.04.026_bb0200","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/157015912800604542","article-title":"Immunomodulation mechanism of antidepressants: interactions between serotonin\/norepinephrine balance and Th1\/Th2 balance","volume":"10","author":"Martino","year":"2012","journal-title":"Curr. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2017.04.026_bb0205","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0924-977X(01)00081-5","article-title":"Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis","volume":"11","author":"Mikova","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5\u20136","key":"10.1016\/j.pnpbp.2017.04.026_bb0210","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0306-9877(03)00207-X","article-title":"Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression","volume":"61","author":"Myint","year":"2003","journal-title":"Med. Hypotheses"},{"issue":"1\u20132","key":"10.1016\/j.pnpbp.2017.04.026_bb0215","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jad.2006.07.013","article-title":"Kynurenine pathway in major depression: evidence of impaired neuroprotection","volume":"98","author":"Myint","year":"2007","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2017.04.026_bb0220","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pnpbp.2013.09.016","article-title":"BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine","volume":"48","author":"Ninan","year":"2014","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.04.026_bb0225","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1192\/bjp.bp.105.011015","article-title":"2006. Antidepressant therapy and C-reactive protein levels","volume":"188","author":"O'Brien","year":"2006","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.04.026_bb0230","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.pbb.2012.12.003","article-title":"Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration","volume":"103","author":"Ohgi","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"2","key":"10.1016\/j.pnpbp.2017.04.026_bb0235","first-page":"55","article-title":"The level of kynurenic acid and selected cytokines during antidepresssive treatment","volume":"9","author":"Olajossy","year":"2014","journal-title":"Neuropsychiatria Neuropsychologia"},{"issue":"4","key":"10.1016\/j.pnpbp.2017.04.026_bb0240","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/15622970802573246","article-title":"Pro-inflammatory biomakers in depression: treatment with venlafaxine","volume":"10","author":"Piletz","year":"2009","journal-title":"World J. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2017.04.026_bb0245","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1179\/1476830513Y.0000000066","article-title":"Effects of zinc supplementation on efficacy of antidepressant therapy, inflammatory cytokines, and brain-derived neurotrophic factor in patients with major depression","volume":"17","author":"Ranjbar","year":"2014","journal-title":"Nutr. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.04.026_bb0250","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s004060170058","article-title":"Different immune patterns in melancholic and non-melancholic major depression","volume":"251","author":"Rothermundt","year":"2001","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2017.04.026_bb0255","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/art.27304","article-title":"Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors","volume":"62","author":"Sacre","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.pnpbp.2017.04.026_bb0260","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.psychres.2016.02.052","article-title":"Pro- and anti-inflammatory cytokines, but not CRP, are inversely correlated with severity and symptoms of major depression","volume":"239","author":"Schmidt","year":"2016","journal-title":"Psychiatry Res."},{"issue":"16","key":"10.1016\/j.pnpbp.2017.04.026_bb0265","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/mp.2010.52","article-title":"Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression","volume":"2011","author":"Shelton","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.04.026_bb0270","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1749-6632.1995.tb32372.x","article-title":"Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine","volume":"762","author":"S\u0142uzewska","year":"1995","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"10","key":"10.1016\/j.pnpbp.2017.04.026_bb0275","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.euroneuro.2015.06.007","article-title":"Inflammation and clinical response to treatment in depression: a meta-analysis","volume":"25","author":"Strawbridge","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.04.026_bb0280","doi-asserted-by":"crossref","first-page":"76396","DOI":"10.1155\/2007\/76396","article-title":"Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy","volume":"2007","author":"Sutcigil","year":"2007","journal-title":"Clin. Dev. Immunol."},{"issue":"4","key":"10.1016\/j.pnpbp.2017.04.026_bb0285","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00213-003-1566-z","article-title":"Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder","volume":"170","author":"Tuglu","year":"2003","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pnpbp.2017.04.026_bb0290","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jad.2013.06.004","article-title":"CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies","volume":"150","author":"Valkanova","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2017.04.026_bb0295","series-title":"The Global Burden of Disease 2004 Update","author":"World Health Organization","year":"2008"},{"issue":"5","key":"10.1016\/j.pnpbp.2017.04.026_bb0300","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/hup.2333","article-title":"Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder","volume":"28","author":"Yoshimura","year":"2013","journal-title":"Hum Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2017.04.026_bb0305","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/npp.2011.277","article-title":"Interleukin-1\u03b2: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis","volume":"37","author":"Zunszain","year":"2012","journal-title":"Neuropsychopharmacology"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584617300659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584617300659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T05:11:44Z","timestamp":1529644304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584617300659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":60,"alternative-id":["S0278584617300659"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2017.04.026","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of antidepressant treatment on peripheral inflammation markers \u2013 A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2017.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}